CSIMarket


Esperion Therapeutics Inc   (ESPR)
Other Ticker:  
 

Esperion Therapeutics Inc

ESPR's Fundamental analysis








Looking into Esperion Therapeutics Inc growth rates, revenue grew by 466.14 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 36

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -0.33 %

Esperion Therapeutics Inc realized net income compared to net loss a year ago in I. Quarter 2024

More on ESPR's Growth


Esperion Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 6.66 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.37.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.


More on ESPR's Valuation
 
 Total Debt (Millions $) 262
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 4.93
 Tangible Book Value (Per Share $) -1.55

Esperion Therapeutics Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 6.66 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.37.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.


More on ESPR's Valuation

  Market Capitalization (Millions $) 544
  Shares Outstanding (Millions) 190
  Employees -
  Revenues (TTM) (Millions $) 230
  Net Income (TTM) (Millions $) -87
  Cash Flow (TTM) (Millions $) 82
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) 262
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 4.93
  Tangible Book Value (Per Share $) -1.55

  Market Capitalization (Millions $) 544
  Shares Outstanding (Millions) 190
  Employees -
  Revenues (TTM) (Millions $) 230
  Net Income (TTM) (Millions $) -87
  Cash Flow (TTM) (Millions $) 82
  Capital Exp. (TTM) (Millions $) 0


    ESPR's Profitability Comparisons
Esperion Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 52.47 %.

Esperion Therapeutics Inc net profit margin of 44.3 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 14 in Healthcare sector and number 142 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.22
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.9
  Inventory Turnover Ratio (TTM) -



Esperion Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 52.47 %.

Esperion Therapeutics Inc net profit margin of 44.3 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 14 in Healthcare sector and number 142 in S&P 500.

More on ESPR's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com